- Conditions
- Heart Failure With Preserved Ejection Fraction, Chronic Heart Failure, Type 2 Diabetes Mellitus
- Interventions
- Empagliflozin, Sitagliptin
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39,614 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 21,535
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- MedtronicMinimed 670G 3.0 hybrid closed loop system, Medtronic Minimed 670G 4.0 AHCL with Guardian Sensor (3) continuous glucose monitoring sensor.
- Device
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 14 Years to 30 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- New Haven, Connecticut • Gainesville, Florida • Boston, Massachusetts + 1 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Ivonescimab Injection, Pembrolizumab Injection
- Biological
- Lead sponsor
- Summit Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 97
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 86 more
- Conditions
- Neuroblastoma
- Interventions
- carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
- Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 12 Years
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2021
- U.S. locations
- 166
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
- Conditions
- Amyotrophic Lateral Sclerosis, Alzheimer Disease, Mild Cognitive Impairment
- Interventions
- Baricitinib
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Charlestown, Massachusetts
- Conditions
- Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone
- Interventions
- Hydrocortisone, Placebo
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism
- Interventions
- Fondaparinux
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acneiform Eruption Due to Chemical, Xerosis Cutis, Paronychia
- Interventions
- HT-001 2% Topical Gel, HT-001 1% Topical Gel, HT-001 0.5% Topical Gel, HT-001 Placebo
- Drug
- Lead sponsor
- Hoth Therapeutics, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Irvine, California • Orange, California • Miami, Florida + 6 more
- Conditions
- Carotid Stenosis
- Interventions
- Gadobutrol (Gadovist, BAY86-4875)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 479 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Jacksonville, Florida • Savannah, Georgia + 12 more
- Conditions
- Cardiopulmonary Resuscitation, Respiratory Physiology
- Interventions
- Mouth-to-mouth or mouth-to-nose breathing
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung, Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Colorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms, Colorectal Tumors, Neoplasms, Colorectal
- Interventions
- JDQ443, trametinib, Ribociclib, cetuximab
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Advanced or Metastatic Melanoma
- Interventions
- Nivolumab, Ipilimumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 11
- States / cities
- Tampa, Florida • Indianapolis, Indiana • Boston, Massachusetts + 4 more
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, AV Block, LBBB, RBBB, Intraventricular Conduction Delay, Pacing-Induced Cardiomyopathy
- Interventions
- His/LBBP, BiVP
- Device
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 57
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Little Rock, Arkansas + 46 more
- Conditions
- Narcolepsy Type 1
- Interventions
- Oveporexton, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Redwood City, California • Santa Ana, California + 12 more
- Conditions
- Choroideremia, CHM (Choroideremia) Gene Mutations
- Interventions
- AAV2-hCHM
- Biological
- Lead sponsor
- Spark Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Constipation
- Interventions
- Not listed
- Lead sponsor
- The SmartPill Corporation
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 178 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 8
- States / cities
- Scottsdale, Arizona • Iowa City, Iowa • Kansas City, Kansas + 5 more
- Conditions
- Relapsed Multiple Myeloma, Refractory Multiple Myeloma
- Interventions
- Nivolumab, Ixazomib, Dexamethasone, Cyclophosphamide
- Drug
- Lead sponsor
- Andrew Yee, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Danvers, Massachusetts
- Conditions
- Renal Function
- Interventions
- aliskiren, placebo, VTP-27999
- Drug
- Lead sponsor
- Vitae Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Liver Transplantation, Liver Preservation for Transplant
- Interventions
- OCS™ Liver System, Control
- Device · Other
- Lead sponsor
- TransMedics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 20
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 17 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab, Paclitaxel, Epirubicin, Doxorubicin, Docetaxel, Cyclophosphamide, 5-Fluorouracil
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,846 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Oakland, California • Roseville, California + 44 more
- Conditions
- Normal Physiology
- Interventions
- Pupillometry, Light box exposure
- Device
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Leukemia
- Interventions
- gemtuzumab ozogamicin, observation, Cytosine arabinoside, Daunomycin
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 637 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 255
- States / cities
- Anchorage, Alaska • Fort Smith, Arkansas • Little Rock, Arkansas + 161 more
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, GBM, Anaplastic Astrocytoma, Oligo-Astrocytoma, Gliosarcoma
- Interventions
- 131-I-TM-601, 131I-TM601
- Drug
- Lead sponsor
- TransMolecular
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Body Dysmorphic Disorder
- Interventions
- d-cycloserine, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts